Personalized immune cells tested as new weapon against lung cancer
NCT ID NCT07271446
Summary
This early-stage study tested whether a personalized immune cell therapy called PB101 is safe when given alongside standard lung cancer drugs. Researchers collected immune cells from 8 patients with advanced EGFR-mutated lung cancer, grew them in a lab, and infused them back to help fight cancer. The main goal was to check for side effects and determine safe dosing before larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital
Taipei, Taiwan, 114202, Taiwan
Conditions
Explore the condition pages connected to this study.